Werewolf Therapeutics Unveils Tumor-Selective INDUKINE Data at SITC 2025

Reuters

Nov 07

Werewolf <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Unveils Tumor-Selective INDUKINE Data at SITC 2025

Werewolf Therapeutics Inc. announced new preclinical data expanding its PREDATOR® platform at the 2025 Society for Immunotherapy of Cancer's $(SITC)$ 40th Annual Meeting, held November 5-9, 2025. The company presented first-in-kind real-time pharmacokinetic data demonstrating that WTX-124 is selectively activated in tumors while sparing healthy tissue in a mouse tumor model. Additional findings included the development of the novel INDUCER™ T Cell Engager Platform, which utilizes a differentiated masking approach to mitigate systemic toxicities, and a sequential dosing regimen of INDUKINE™ molecules that showed potent antitumor activity with improved safety in preclinical studies. The results were presented at the SITC meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Werewolf Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9570843-en) on November 07, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2581364886"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581364886\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581364886?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 22:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581364886","market":"us","top_or_hot":-1,"title":"Werewolf Therapeutics Unveils Tumor-Selective INDUKINE Data at SITC 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Werewolf <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Unveils Tumor-Selective INDUKINE Data at SITC 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Werewolf Therapeutics Inc. announced new preclinical data expanding its PREDATOR® platform at the 2025 Society for Immunotherapy of Cancer's <a href=\"https://laohu8.com/S/SITC\">$(SITC)$</a> 40th Annual Meeting, held November 5-9, 2025. The company presented first-in-kind real-time pharmacokinetic data demonstrating that WTX-124 is selectively activated in tumors while sparing healthy tissue in a mouse tumor model. Additional findings included the development of the novel INDUCER™ T Cell Engager Platform, which utilizes a differentiated masking approach to mitigate systemic toxicities, and a sequential dosing regimen of INDUKINE™ molecules that showed potent antitumor activity with improved safety in preclinical studies. The results were presented at the SITC meeting.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Werewolf Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9570843-en) on November 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Werewolf Therapeutics Unveils Tumor-Selective INDUKINE Data at SITC 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWerewolf Therapeutics Unveils Tumor-Selective INDUKINE Data at SITC 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-07 22:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Werewolf <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Unveils Tumor-Selective INDUKINE Data at SITC 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Werewolf Therapeutics Inc. announced new preclinical data expanding its PREDATOR® platform at the 2025 Society for Immunotherapy of Cancer's <a href=\"https://laohu8.com/S/SITC\">$(SITC)$</a> 40th Annual Meeting, held November 5-9, 2025. The company presented first-in-kind real-time pharmacokinetic data demonstrating that WTX-124 is selectively activated in tumors while sparing healthy tissue in a mouse tumor model. Additional findings included the development of the novel INDUCER™ T Cell Engager Platform, which utilizes a differentiated masking approach to mitigate systemic toxicities, and a sequential dosing regimen of INDUKINE™ molecules that showed potent antitumor activity with improved safety in preclinical studies. The results were presented at the SITC meeting.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Werewolf Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9570843-en) on November 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2210150020.SGD","symbol_name":"Natixis Thematics Subscription Economy R/A SGD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nNDL9qBD2k:1","article_id":"2581364886","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581364886","pubTimestamp":1762524018,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Werewolf Therapeutics Inc. announced new preclinical data expanding its PREDATOR platform at the 2025 Society for Immunotherapy of Cancer's  40th Annual Meeting, held November 5-9, 2025. The company presented first-in-kind real-time pharmacokinetic data demonstrating that WTX-124 is selectively activated in tumors while sparing healthy tissue in a mouse tumor model. Additional findings included the development of the novel INDUCER T Cell Engager Platform, which utilizes a differentiated masking approach to mitigate systemic toxicities, and a sequential dosing regimen of INDUKINE molecules that showed potent antitumor activity with improved safety in preclinical studies. The results were presented at the SITC meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4539":"次新股","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4588":"碎股","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4112":"金融交易所和数据","BK4585":"ETF&股票定投概念","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4139":"生物科技","HOWL":"Werewolf Therapeutics, Inc.","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","NDAQ":"纳斯达克OMX交易所","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC"},"translate_title":"Werewolf Therapeutics在SITC 2025上公布肿瘤选择性诱导因子数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HOWL":0.9,"NDAQ":0.9},"content_text":"Werewolf Therapeutics Unveils Tumor-Selective INDUKINE Data at SITC 2025\n    \n\n        Werewolf Therapeutics Inc. announced new preclinical data expanding its PREDATOR® platform at the 2025 Society for Immunotherapy of Cancer's $(SITC)$ 40th Annual Meeting, held November 5-9, 2025. The company presented first-in-kind real-time pharmacokinetic data demonstrating that WTX-124 is selectively activated in tumors while sparing healthy tissue in a mouse tumor model. Additional findings included the development of the novel INDUCER™ T Cell Engager Platform, which utilizes a differentiated masking approach to mitigate systemic toxicities, and a sequential dosing regimen of INDUKINE™ molecules that showed potent antitumor activity with improved safety in preclinical studies. The results were presented at the SITC meeting.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Werewolf Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9570843-en) on November 07, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}